Protean Presents on OncoSignal at SABCS 2021
Protean Presents OncoSignal, a New Way to Identify Therapeutic Targets
Protean BioDiagnostics presents a new method to identify potential therapeutic targets in breast cancer.
The method called OncoSignal Analysis utilizes mRNA transcriptional measurements to accurately calculate the pathway activity of seven key oncogenic signaling pathways.
The tissue testing method is complementary to other methods such as immunohistochemistry and DNA sequencing and could be used to better analyze breast and other cancers to improve therapy selection for cancer patients.
Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS® and the author of this poster.
Contact Dr. Anthony Magliocco at magliocco@proteanbiodx.com for more information.
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.